open access

Vol 24, No 5 (2017)
Original articles — Clinical cardiology
Published online: 2017-03-09
Get Citation

Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial

Leili Iranirad, Seyed Fakhreddin Hejazi, Mohammad Saleh Sadeghi, Shahram Arsang Jang
DOI: 10.5603/CJ.a2017.0028
·
Pubmed: 28281738
·
Cardiol J 2017;24(5):502-507.

open access

Vol 24, No 5 (2017)
Original articles — Clinical cardiology
Published online: 2017-03-09

Abstract

Background: Contrast-induced nephropathy (CIN) remains to be a potentially serious complication of radiographic procedures and is the third leading cause of the acute kidney injury (AKI) among hospitalized patients. This clinical trial was performed to assess the preventive effect of oral nicorandil on CIN in high-risk patients undergoing cardiac catheterization.

Methods: In this prospective, randomized, controlled trial, 128 patients with at least two risk factors for CIN undergoing elective percutaneous coronary intervention (PCI) were randomly assigned to either the nicorandil group or the control group. Patients in the nicorandil group (n = 64) received 10 mg nicorandil, daily from 30 min before and up to 3 days after procedure and intravenous hydration for 2 h before and 6 h after the procedure, whereas patients in the control group (n = 64) just received intravenous hydration. Serum creatinine (SCr) was measured before contrast exposure and at 72 h. CIN was defined as an increase of 25% in SCr or > 0.5 mg/dL 72 h after contrast administration.

Results: Contrast-induced nephropathy occurred in 14 out of 64 (21.9%) patients in the control group and in 3 out of 64 (4.7%) patients in the nicorandil group. There was a significant difference in the incidence of CIN between the two groups at 72 h after administering the radiocontrast agent (p = 0.008). Moreover, there were significant differences between the two groups in SCr and estimated glomerular filtration rate 72 h after radiocontrast administration (p < 0.05).

Conclusions: The findings revealed that oral nicorandil had substantial efficacy over hydration protocol for the development of CIN in high-risk patients undergoing cardiac catheterization.  

Abstract

Background: Contrast-induced nephropathy (CIN) remains to be a potentially serious complication of radiographic procedures and is the third leading cause of the acute kidney injury (AKI) among hospitalized patients. This clinical trial was performed to assess the preventive effect of oral nicorandil on CIN in high-risk patients undergoing cardiac catheterization.

Methods: In this prospective, randomized, controlled trial, 128 patients with at least two risk factors for CIN undergoing elective percutaneous coronary intervention (PCI) were randomly assigned to either the nicorandil group or the control group. Patients in the nicorandil group (n = 64) received 10 mg nicorandil, daily from 30 min before and up to 3 days after procedure and intravenous hydration for 2 h before and 6 h after the procedure, whereas patients in the control group (n = 64) just received intravenous hydration. Serum creatinine (SCr) was measured before contrast exposure and at 72 h. CIN was defined as an increase of 25% in SCr or > 0.5 mg/dL 72 h after contrast administration.

Results: Contrast-induced nephropathy occurred in 14 out of 64 (21.9%) patients in the control group and in 3 out of 64 (4.7%) patients in the nicorandil group. There was a significant difference in the incidence of CIN between the two groups at 72 h after administering the radiocontrast agent (p = 0.008). Moreover, there were significant differences between the two groups in SCr and estimated glomerular filtration rate 72 h after radiocontrast administration (p < 0.05).

Conclusions: The findings revealed that oral nicorandil had substantial efficacy over hydration protocol for the development of CIN in high-risk patients undergoing cardiac catheterization.  

Get Citation

Keywords

contrast-induced nephropathy, nicorandil, percutaneous coronary intervention

About this article
Title

Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial

Journal

Cardiology Journal

Issue

Vol 24, No 5 (2017)

Pages

502-507

Published online

2017-03-09

DOI

10.5603/CJ.a2017.0028

Pubmed

28281738

Bibliographic record

Cardiol J 2017;24(5):502-507.

Keywords

contrast-induced nephropathy
nicorandil
percutaneous coronary intervention

Authors

Leili Iranirad
Seyed Fakhreddin Hejazi
Mohammad Saleh Sadeghi
Shahram Arsang Jang

References (21)
  1. Thayssen P, Lassen JF, Jensen SE, et al. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial. Circ Cardiovasc Interv. 2014; 7(2): 216–224.
  2. Cheungpasitporn W, Thongprayoon C, Brabec BA, et al. Oral hydration for prevention of contrast-induced acute kidney injury in elective radiological procedures: a systematic review and meta-analysis of randomized controlled trials. N Am J Med Sci. 2014; 6(12): 618–624.
  3. Wu MY, Hsiang HF, Wong CS, et al. The effectiveness of N-Acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials. Int Urol Nephrol. 2013; 45(5): 1309–1318.
  4. Chyou AC, Thodge A, Feldman DN, et al. Statins in the prevention of contrast-induced nephropathy. Curr Treat Options Cardiovasc Med. 2015; 17(4): 375.
  5. Wong PC, Li Z, Guo J, et al. Pathophysiology of contrast-induced nephropathy. Int J Cardiol. 2012; 158(2): 186–192.
  6. Wu Z, Zhang H, Jin W, et al. The effect of renin-angiotensin-aldosterone system blockade medications on contrast-induced nephropathy in patients undergoing coronary angiography: a meta-analysis. PLoS One. 2015; 10(6): e0129747.
  7. Wessely R, Koppara T, Bradaric C, et al. Contrast Media and Nephrotoxicity Following Coronary Revascularization by Angioplasty Trial Investigators. Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2009; 2(5): 430–437.
  8. Kassis HM, Minsinger KD, McCullough PA, et al. A Review of the use of iloprost, a synthetic prostacyclin, in the prevention of radiocontrast nephropathy in patients undergoing coronary angiography and intervention. Clin Cardiol. 2015; 38(8): 492–498.
  9. Erol T, Tekin A, Katırcıbaşı MT, et al. Efficacy of allopurinol pretreatment for prevention of contrast-induced nephropathy: a randomized controlled trial. Int J Cardiol. 2013; 167(4): 1396–1399.
  10. Çiçek G, Bozbay M, Açıkgöz SK, et al. The ratio of contrast volume to glomerular filtration rate predicts in-hospital and six-month mortality in patients undergoing primary angioplasty for ST-elevation myocardial infarction. Cardiol J. 2015; 22(1): 101–107.
  11. Shimizu S, Saito M, Kinoshita Y, et al. Nicorandil ameliorates ischaemia-reperfusion injury in the rat kidney. Br J Pharmacol. 2011; 163(2): 272–282.
  12. Ko YG, Lee BK, Kang WC, et al. PRINCIPLE Investigators. Preventive effect of pretreatment with intravenous nicorandil on contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography (PRINCIPLE Study). Yonsei Med J. 2013; 54(4): 957–964.
  13. Fan Y, Wei Q, Cai J, et al. Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization. Heart Vessels. 2016; 31(11): 1776–1782.
  14. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004; 44(7): 1393–1399.
  15. Markota D, Markota I, Starcevic B, et al. Prevention of contrast-induced nephropathy with Na/K citrate. Eur Heart J. 2013; 34(30): 2362–2367.
  16. O'Sullivan S, Healy DA, Moloney MC, et al. The role of N-acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: a structured review and meta-analysis. Angiology. 2013; 64(8): 576–582.
  17. Wu MY, Hsiang HF, Wong CS, et al. The effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials. Int Urol Nephrol. 2013; 45(5): 1309–1318.
  18. Gomes VO, Poli de Figueredo CE, Caramori P, et al. N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial. Heart. 2005; 91(6): 774–778.
  19. Gu G, Zhang Y, Lu R, et al. Additional furosemide treatment beyond saline hydration for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015; 8(1): 387–394.
  20. Xing Y, Wei Rb, Tang Lu, et al. Protective effect of salidroside on contrast-induced nephropathy in comparison with N-acetylcysteine and its underlying mechanism. Chin J Integr Med. 2015; 21(4): 266–273.
  21. Tumlin J, Stacul F, Adam A, et al. CIN Consensus Working Panel. Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006; 98(6A): 14K–20K.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl